Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. ADR (NQ: NBTX )

3.450 UNCHANGED
Streaming Delayed Price Updated: 10:40 AM EDT, Mar 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.450
Bid (Size) 1.390 (2)
Ask (Size) 4.280 (2)
Prev. Close 3.450
Today's Range 3.450 - 3.450
52wk Range 2.320 - 7.580
Shares Outstanding 34,432,122
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
From Nanobiotix S.A.
Via Globe NewsWire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via Globe NewsWire

Performance

YTD
-6.88%
-6.88%
1 Month
-8.35%
-8.35%
3 Month
-8.49%
-8.49%
6 Month
-27.06%
-27.06%
1 Year
-52.02%
-52.02%

More News

Read More
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
From Nanobiotix S.A.
Via Globe NewsWire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
From Nanobiotix S.A.
Via Globe NewsWire
Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients
Via Benzinga
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
From Nanobiotix S.A.
Via Globe NewsWire
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
From Nanobiotix S.A.
Via Globe NewsWire
Nanobiotix: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
From Nanobiotix
Via Business Wire
Earnings Scheduled For September 28, 2022
Via Benzinga
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
From Nanobiotix
Via Business Wire
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
Via Benzinga
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
From Nanobiotix
Via Business Wire
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
From Nanobiotix
Via Business Wire
Nanobiotix: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.